drugset
drugset / Trial / NCT03029104

Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

NCT03029104 ↗

Phase 2 Terminated 2228 enrolled Cxlusa
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will assess changes in visual acuity and corneal symmetry after corneal collagen cross-linking (CXL) of asymmetric corneas.

Timeline

Start
2016-12-21
Primary completion
2020-12-27
Completion
2020-12-27

Outcome

Outcome not reported

Stopped: “Sufficient clinical results obtained to support study endpoints.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background CXLO Corneal Strengthening Solution Other / unclassified — —

Indications

keratoconus photosensitivity disease